The SELECT trial (N=17,604) later showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease, even without diabetes [17]
The development of triple agonists (e.g., GLP-1/GIP/glucagon agonists like Retatrutide) or other multi-target agents (e.g., GLP-1/amylin/GIP) represents the next frontier in drug discovery (31)
You might notice immediate reactions to fragrances, cleaning products, or building materials that didn't bother you before, plus increased sensitivity to multiple substances rather than just one trigger
These observations are more broadly relevant to drug discovery at peptide GPCRs for which ligand acylation is a valid approach to improve pharmacokinetics
If side effects make eating difficult, adjust your food choices and meal timing rather than skipping meals altogether